A RANDOMIZED STUDY OF THE EFFECTS OF ADENINE-ARABINOSIDE 5'-MONOPHOSPHATE (SHORT OR LONG COURSES) AND LYMPHOBLASTOID INTERFERON ON HEPATITIS-B VIRUS-REPLICATION
A RANDOMIZED STUDY OF THE EFFECTS OF ADENINE-ARABINOSIDE 5'-MONOPHOSPHATE (SHORT OR LONG COURSES) AND LYMPHOBLASTOID INTERFERON ON HEPATITIS-B VIRUS-REPLICATION
复制标题
DOI：
10.1002/hep.1840050612
复制
发表时间：
1985-01-01
期刊：
影响因子：
13.5
通讯作者：
THOMAS, HC
中科院分区：
文献类型：
--
作者：
LOK, ASF;NOVICK, DM;THOMAS, HC
先前的随机对照研究显示，在一个月的阿糖腺苷-5“-单磷酸疗程的1年内，HBe抗原/抗体血清转换率为30%;对照组未发生血清转换。在这项来自同一人群的患者研究中，45例慢性肝病的B型肝炎病毒携带者被随机分配接受短疗程（4周）的阿糖腺苷-5“-单磷酸、长疗程（7 - 8周）的阿糖腺苷-5”-单磷酸或12周疗程的淋巴母细胞干扰素。4名接受短期阿糖腺苷-5“-单磷酸治疗的患者和5名接受干扰素治疗的患者在治疗12个月内发生了B型肝炎病毒复制的长期抑制，血清B型肝炎病毒DNA消失和HBeAg清除。在9名应答者中，4名也失去了HBsAg。对抗病毒治疗的反应伴随着肝病改善的临床和生化证据。接受长期阿糖腺苷-5 ''-单磷酸治疗的患者无反应。周围神经病变和肌痛是最严重的不良反应，影响3名接受短期阿糖腺苷-5“-单磷酸治疗的患者和8名接受长期治疗的患者。每周三次干扰素给药耐受性良好。进一步的研究，以确定这些亚组的“反应患者”和大规模的抗病毒治疗的对照试验的特点是指。
A previous randomized controlled study has shown a 30% rate of HBe antigen/antibody seroconversion within 1 year of a month course of adenine arabinoside-5''-monophosphate; no seroconversion occurred in the control group. In this study of patients derived from the same population, 45 hepatitis B virus carriers with chronic liver disease were randomized to receive either a short (4-week) course of adenine arabinoside-5''-monophosphate, a long (7 to 8-week) course of adenine arabinoside-5''-monophosphate or a 12-week course of lymphoblastoid interferon. Long-lasting suppression of hepatitis B virus replication with disappearance of serum hepatitis B virus DNA and clearance of HBeAg occurred within 12 months of treatment in four patients who received the short course of adenine arabinoside-5''-monophosphate and in five who received interferon. Of the nine responders, four also lost HBsAg. A response to antiviral therapy was accompanied by clinical and biochemical evidence of improvement in liver disease. None of the patients who received a long course of adenine arabinoside-5''-monophosphate responded. Peripheral neuropathy and myalgia were the most serious adverse effect affecting three recipients of the short course of adenine arabinoside-5''-monophosphate and eight recipients of the long course. Thrice weekly administration of interferon was well-tolerated. Further studies to identify the characteristics of the "responder patients" and large-scale controlled trials of antiviral therapy in these subgroups are indicated.